Arrowhead Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Anzalone Christopher Richard unloaded Company’s shares for reported $0.58 million on Apr 11 ’25. In the deal valued at $11.49 per share,50,800 shares were sold. As a result of this transaction, Anzalone Christopher Richard now holds 3,921,255 shares worth roughly $61.56 million.
Then, Anzalone Christopher Richard sold 50,000 shares, generating $543,500 in total proceeds. Upon selling the shares at $10.87, the Chief Executive Officer now owns 3,972,055 shares.
Before that, Anzalone Christopher Richard sold 40,322 shares. Arrowhead Pharmaceuticals Inc shares valued at $406,145 were divested by the Chief Executive Officer at a price of $10.07 per share. As a result of the transaction, Anzalone Christopher Richard now holds 4,022,055 shares, worth roughly $63.15 million.
Goldman initiated its Arrowhead Pharmaceuticals Inc [ARWR] rating to a Neutral in a research note published on June 05, 2024; the price target was $31. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Citigroup began covering ARWR with “Neutral” recommendation on September 19, 2023. TD Cowen started covering the stock on July 21, 2023. It rated ARWR as “an Outperform”.
Price Performance Review of ARWR
On Monday, Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] saw its stock fall -0.25% to $15.70. Over the last five days, the stock has lost -5.25%. Arrowhead Pharmaceuticals Inc shares have fallen nearly -16.49% since the year began. Nevertheless, the stocks have fallen -39.08% over the past one year. While a 52-week high of $30.41 was reached on 02/07/25, a 52-week low of $9.57 was recorded on 04/07/25.
Levels Of Support And Resistance For ARWR Stock
The 24-hour chart illustrates a support level at 15.44, which if violated will result in even more drops to 15.18. On the upside, there is a resistance level at 15.92. A further resistance level may holdings at 16.14.
